NPPB and pulmonary arterial hypertension: A number of studies have shown that maxitengtan can significantly reduce the mortality or hospitalization rate of patients with PAH and improve 6MWD, cardiac function, quality of life, hemodynamic parameters and NT–proBNP[57–59].